Retatrutide vs Zepbound: Which Eli Lilly Drug Produces More Weight Loss?

Overview

Retatrutide and Zepbound (tirzepatide) are both developed by Eli Lilly and represent the company’s two-pronged approach to next-generation obesity pharmacotherapy. Zepbound (tirzepatide 5, 10, or 15 mg) is an FDA-approved dual GIP/GLP-1 receptor agonist indicated for chronic weight management. Retatrutide (LY3437943) is an investigational triple agonist that adds glucagon receptor activation to the GIP/GLP-1 foundation, currently in Phase 3 development.

With the release of Phase 3 TRIUMPH-4 data in December 2025 showing -28.7% weight loss with retatrutide, the question of how these two Eli Lilly molecules compare has become even more compelling. This comparison examines what glucagon receptor agonism adds to an already highly effective dual agonist backbone.

Important note: No head-to-head trial has compared retatrutide to tirzepatide. Cross-trial comparisons are provided for educational context and carry significant methodological limitations.

Why This Comparison Matters

This comparison is uniquely informative for several reasons:

• Both drugs share two of three receptor targets (GIP and GLP-1), making this an ideal natural experiment for evaluating the incremental benefit of glucagon receptor agonism
• Both are from the same manufacturer, raising important questions about how Eli Lilly will position these products relative to each other
• With TRIUMPH-4 Phase 3 data now showing -28.7% weight loss, the comparison has moved from Phase 2 speculation to Phase 3-level evidence
• Millions of patients currently taking Zepbound will want to understand whether the next-generation option offers meaningful additional benefit

Mechanism of Action

Zepbound (Tirzepatide)

Tirzepatide is a 39-amino-acid peptide built on a GIP backbone with engineered GLP-1 receptor cross-reactivity. It activates two incretin receptors:

• GIP receptor activation contributes to adipose tissue remodeling, enhanced beta-cell insulin secretion, and potentially central appetite regulation through hypothalamic pathways
• GLP-1 receptor activation drives appetite suppression, delayed gastric emptying, glucose-dependent insulin secretion, and glucagon suppression

Tirzepatide shows approximately 5-fold higher potency at the GIP receptor relative to native GIP, while maintaining clinically significant GLP-1 receptor activation. This dual mechanism produces weight loss and glycemic effects exceeding those of selective GLP-1 receptor agonists alone.

Retatrutide

Retatrutide shares tirzepatide’s GIP and GLP-1 receptor activity but adds a third target: the glucagon receptor (GCGR). This addition introduces distinct metabolic effects:

• Increased hepatic energy expenditure through stimulation of glucagon-mediated thermogenesis and mitochondrial fatty acid oxidation
• Enhanced lipid mobilization from adipose tissue and accelerated hepatic fat clearance
• Amino acid catabolism and ureagenesis, contributing to overall energy expenditure

The glucagon receptor component represents the critical differentiator. While both molecules reduce caloric intake, retatrutide simultaneously increases energy expenditure, creating a dual deficit that explains its greater weight loss in clinical data.

TRIUMPH-4 Phase 3 Results: A New Benchmark

The December 2025 release of TRIUMPH-4 data transformed the retatrutide-versus-Zepbound comparison from cross-trial Phase 2/Phase 3 speculation to a Phase 3-versus-Phase 3 discussion. TRIUMPH-4 enrolled 768 adults with obesity and knee osteoarthritis and demonstrated:

The -28.7% weight loss at 12 mg represents the largest weight reduction ever reported for any pharmaceutical agent in a Phase 3 clinical trial, substantially exceeding Zepbound’s -22.5% in SURMOUNT-1. Even the lower 8 mg dose of retatrutide (-25.4%) exceeded Zepbound’s highest dose.

Efficacy Comparison

Weight Loss: Phase 3 Data

The ~6 percentage point gap between these agents at the highest response thresholds (≥20% weight loss) is clinically meaningful and likely reflects the contribution of glucagon receptor-mediated energy expenditure. At more modest thresholds (≥5%), both agents achieve near-universal response, confirming that the shared GIP/GLP-1 agonism drives the foundation of efficacy.

Liver Fat Reduction

This is where glucagon receptor activation may confer the most distinctive advantage. In Phase 2 data, retatrutide achieved approximately 82% relative reduction in hepatic fat content, meaningfully greater than that observed with tirzepatide in MASLD-focused studies. Glucagon receptor agonism directly stimulates hepatic fatty acid oxidation, providing a mechanistic rationale for superior liver fat clearance beyond what weight loss alone produces.

Glycemic Effects

Both agents demonstrate substantial glycemic improvements. Tirzepatide achieved HbA1c reductions of approximately 2.0 to 2.4% in Phase 3 diabetes trials (SURPASS program). Retatrutide showed HbA1c reductions of approximately 2.02% in its Phase 2 diabetes cohort. These effects appear broadly comparable, with the dual and triple agonist approaches both providing robust glucose control.

Safety Comparison

Gastrointestinal Tolerability

GI adverse event rates appear broadly similar across both agents, consistent with the shared GLP-1 receptor activation that primarily drives these effects. The GIP receptor activation present in both may provide some mitigation of GLP-1-driven nausea.

TRIUMPH-4 Safety: Dysesthesia Signal

TRIUMPH-4 revealed a new safety finding for retatrutide: dysesthesia (abnormal sensory sensations such as numbness, tingling, or burning) was reported in 20.9% of participants at the 12 mg dose compared with 0.7% on placebo. This was not observed in Phase 2 trials, likely due to smaller sample sizes. The mechanism behind this effect is under investigation, and ongoing Phase 3 trials will further characterize its incidence, severity, and clinical significance.

Zepbound does not have a comparable dysesthesia signal in its clinical trial database.

Glucagon-Specific Considerations

Retatrutide’s glucagon receptor component introduces theoretical considerations not applicable to tirzepatide:

• Hepatic glucose output stimulation, which could counteract glycemic control in diabetes. Phase 2 data suggest this is adequately offset by the concurrent GLP-1 and GIP-mediated insulin effects.
• Potential effects on amino acid metabolism and lean mass preservation, which require further characterization.
• Heart rate effects appeared comparable between the two agents (modest increases of 2 to 4 bpm).

Cardiovascular Data

Neither agent has completed a dedicated cardiovascular outcomes trial for the obesity indication. Tirzepatide’s SURPASS-CVOT trial in type 2 diabetes is ongoing, while retatrutide has no cardiovascular outcomes data. Both showed favorable effects on cardiovascular risk factors (blood pressure, lipids) in their respective trials.

Eli Lilly Portfolio Strategy

Both molecules being from Eli Lilly raises an important question about portfolio positioning. The two agents likely serve complementary rather than competing roles:

• Zepbound is the established, approved product generating revenue and building market presence in the obesity space. It has demonstrated best-in-class efficacy among approved anti-obesity medications.
• Retatrutide represents the next-generation candidate that could extend Eli Lilly’s leadership if Phase 3 trials confirm its Phase 2 and early Phase 3 efficacy signal. It may be positioned for patients requiring greater weight loss magnitude or those with specific comorbidities (such as MASLD) where glucagon receptor activation provides added benefit.

This strategy allows Eli Lilly to serve different patient segments and maintain competitive advantage as the obesity pharmacotherapy landscape evolves.

Current Status and Availability

Zepbound

Zepbound is FDA-approved (November 2023) and commercially available for chronic weight management in adults with BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity. It is prescribed by healthcare providers and available through standard pharmacy channels, though supply constraints have affected availability at times.

Retatrutide

Retatrutide is investigational as of March 2026. The Phase 3 TRIUMPH program includes 7 trials (TRIUMPH 1-7), plus the TRANSCEND (type 2 diabetes) and SYNERGY (MASH) studies. TRIUMPH-4 results have been published, and additional Phase 3 readouts are expected in late 2026-2027. No NDA has been filed. The earliest possible FDA approval is estimated at late 2027-2028. Retatrutide is available only through enrollment in authorized clinical trials.

Key Differences Summary

Dosing and Administration Comparison

Both medications follow similar administration patterns as once-weekly subcutaneous injections:

Both agents require gradual dose escalation to minimize GI side effects. The patient experience in terms of injection routine would be very similar.

Who Might Benefit From Each

Zepbound Is the Right Choice For

• Patients who need treatment now — Zepbound is approved and available
• Patients with moderate obesity (BMI 30-40) seeking proven efficacy
• Patients who want an established safety profile with comprehensive Phase 3 data
• Patients whose insurance coverage supports Zepbound for weight management

Retatrutide May Be More Appropriate For (Once Approved)

• Patients with severe obesity (BMI ≥40) who need the greatest possible weight reduction
• Patients with significant MASLD/MASH who would benefit from direct hepatic fat clearance via glucagon receptor activation
• Patients who have tried Zepbound but need additional weight loss
• Patients with obesity-related comorbidities (like knee osteoarthritis, as studied in TRIUMPH-4) where maximal weight loss improves the comorbid condition

The Weight Loss Gap in Context

The approximately 6 percentage point gap between Zepbound (-22.5%) and retatrutide (-28.7%) translates to meaningful real-world differences. For a patient weighing 250 pounds (113 kg):

• Zepbound: Expected loss of approximately 56 pounds (25 kg)
• Retatrutide: Expected loss of approximately 72 pounds (33 kg)
• Difference: Approximately 16 additional pounds (7 kg) of weight loss

This incremental weight loss can have outsized clinical impact at the higher end, improving joint function, sleep apnea severity, cardiovascular risk factors, and metabolic health beyond what is achieved at lower weight loss thresholds.

Clinical Implications

Zepbound is currently the most effective FDA-approved anti-obesity medication, with Phase 3 data supporting weight loss exceeding 20% in the majority of patients at the highest dose. It has an established safety profile, is commercially available, and is building an expanding evidence base across multiple indications.

Retatrutide’s TRIUMPH-4 Phase 3 data confirmed its potential for even greater weight loss (-28.7% at 12 mg), validating the Phase 2 signal and establishing a new benchmark for pharmacological weight reduction. The glucagon receptor component provides a mechanistic rationale for these improvements. However, the dysesthesia signal identified in TRIUMPH-4 requires careful characterization in ongoing trials.

The relationship between these two molecules within Eli Lilly’s portfolio will ultimately be determined by the complete Phase 3 data for retatrutide, regulatory decisions, the significance of the dysesthesia finding, pricing strategy, and the clinical scenarios where the addition of glucagon receptor agonism provides meaningful incremental benefit over the already substantial effects of dual GIP/GLP-1 agonism.

Frequently Asked Questions

How much more weight loss does retatrutide produce compared to Zepbound?

In Phase 3 data, retatrutide 12 mg achieved -28.7% weight loss at 68 weeks (TRIUMPH-4) compared to Zepbound’s -22.5% at 72 weeks (SURMOUNT-1), a difference of approximately 6 percentage points. However, these are cross-trial comparisons with different patient populations, and a direct head-to-head trial has not been conducted.

Will retatrutide replace Zepbound?

This is unlikely. Eli Lilly has positioned both molecules as complementary products. Zepbound serves as the established, approved treatment for most patients with obesity, while retatrutide may be positioned for patients who need the greatest possible weight loss or who have comorbidities like fatty liver disease. Both products are expected to coexist in Eli Lilly’s metabolic portfolio.

When can I switch from Zepbound to retatrutide?

Retatrutide is not yet approved and is available only through clinical trials as of March 2026. Patients currently taking Zepbound should not discontinue their treatment in anticipation of retatrutide. The earliest possible commercial availability is late 2027-2028, assuming successful Phase 3 completion and FDA approval.

What is the dysesthesia side effect found in TRIUMPH-4?

Dysesthesia refers to abnormal sensations such as numbness, tingling, or burning. In TRIUMPH-4, it was reported in 20.9% of participants receiving retatrutide 12 mg compared with 0.7% on placebo. This was a new finding not seen in Phase 2 trials. The mechanism is under investigation, and ongoing Phase 3 trials will determine how significant this side effect is clinically.

Are retatrutide and Zepbound both weekly injections?

Yes. Both retatrutide and Zepbound are administered as once-weekly subcutaneous injections using pre-filled pen devices. The injection routine, including site rotation and storage requirements, would be similar for both medications.

Does retatrutide work better for liver fat than Zepbound?

Yes, based on available data. Retatrutide achieved approximately 82% relative liver fat reduction in Phase 2, substantially greater than the moderate reductions observed with tirzepatide. This is because retatrutide’s glucagon receptor component directly stimulates hepatic fatty acid oxidation — a mechanism not present in Zepbound. For patients with significant fatty liver disease (MASLD/MASH), this hepatic benefit may be a key differentiator.

What happens to Zepbound patients when retatrutide is approved?

Patients currently taking Zepbound would not need to switch. Zepbound will remain available and effective for the large majority of patients. Retatrutide would become an additional option for patients who need greater weight loss, have significant liver disease, or have not achieved adequate results with Zepbound. The decision to switch would be made between individual patients and their healthcare providers based on clinical needs and treatment goals.

Is retatrutide’s -28.7% weight loss really that much better than Zepbound’s -22.5%?

The 6 percentage point gap is clinically meaningful. For a 250-pound patient, this represents approximately 16 additional pounds of weight loss. At the population level, more patients reach the ≥20% and ≥25% weight loss thresholds with retatrutide, which are increasingly recognized as clinically important targets. However, both drugs produce weight loss that far exceeds any previously available medications, and Zepbound remains a highly effective treatment.